An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth

BACKGROUND: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-617 for therapy of metastatic castration-resistant prostate cancer have under-lined the clinical potential of targeted alpha therapy. OBJECTIVE AND CONCLUSION: This review describes methods for the production of...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgenstern, Alfred, Apostolidis, Christos, Kratochwil, Clemens, Sathekge, Mike, Krolicki, Leszek, Bruchertseifer, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237921/
https://www.ncbi.nlm.nih.gov/pubmed/29732998
http://dx.doi.org/10.2174/1874471011666180502104524
_version_ 1783371271890796544
author Morgenstern, Alfred
Apostolidis, Christos
Kratochwil, Clemens
Sathekge, Mike
Krolicki, Leszek
Bruchertseifer, Frank
author_facet Morgenstern, Alfred
Apostolidis, Christos
Kratochwil, Clemens
Sathekge, Mike
Krolicki, Leszek
Bruchertseifer, Frank
author_sort Morgenstern, Alfred
collection PubMed
description BACKGROUND: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-617 for therapy of metastatic castration-resistant prostate cancer have under-lined the clinical potential of targeted alpha therapy. OBJECTIVE AND CONCLUSION: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tu-mors, neuroendocrine tumors and prostate cancer.
format Online
Article
Text
id pubmed-6237921
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-62379212018-12-07 An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth Morgenstern, Alfred Apostolidis, Christos Kratochwil, Clemens Sathekge, Mike Krolicki, Leszek Bruchertseifer, Frank Curr Radiopharm Article BACKGROUND: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-617 for therapy of metastatic castration-resistant prostate cancer have under-lined the clinical potential of targeted alpha therapy. OBJECTIVE AND CONCLUSION: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tu-mors, neuroendocrine tumors and prostate cancer. Bentham Science Publishers 2018-12 2018-12 /pmc/articles/PMC6237921/ /pubmed/29732998 http://dx.doi.org/10.2174/1874471011666180502104524 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Morgenstern, Alfred
Apostolidis, Christos
Kratochwil, Clemens
Sathekge, Mike
Krolicki, Leszek
Bruchertseifer, Frank
An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
title An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
title_full An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
title_fullStr An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
title_full_unstemmed An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
title_short An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
title_sort overview of targeted alpha therapy with (225)actinium and (213)bismuth
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237921/
https://www.ncbi.nlm.nih.gov/pubmed/29732998
http://dx.doi.org/10.2174/1874471011666180502104524
work_keys_str_mv AT morgensternalfred anoverviewoftargetedalphatherapywith225actiniumand213bismuth
AT apostolidischristos anoverviewoftargetedalphatherapywith225actiniumand213bismuth
AT kratochwilclemens anoverviewoftargetedalphatherapywith225actiniumand213bismuth
AT sathekgemike anoverviewoftargetedalphatherapywith225actiniumand213bismuth
AT krolickileszek anoverviewoftargetedalphatherapywith225actiniumand213bismuth
AT bruchertseiferfrank anoverviewoftargetedalphatherapywith225actiniumand213bismuth
AT morgensternalfred overviewoftargetedalphatherapywith225actiniumand213bismuth
AT apostolidischristos overviewoftargetedalphatherapywith225actiniumand213bismuth
AT kratochwilclemens overviewoftargetedalphatherapywith225actiniumand213bismuth
AT sathekgemike overviewoftargetedalphatherapywith225actiniumand213bismuth
AT krolickileszek overviewoftargetedalphatherapywith225actiniumand213bismuth
AT bruchertseiferfrank overviewoftargetedalphatherapywith225actiniumand213bismuth

Ejemplares similares